Last edition
News about "dexamethasone "
BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma
Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.
Dexamethasone | 28/09/2026 | By News Bureau | 115
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
Dexamethasone | 14/08/2026 | By News Bureau | 122
Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.
Dexamethasone | 19/02/2026 | By News Bureau | 238
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Dexamethasone | 15/01/2026 | By News Bureau | 178
Lupin Secures US FDA Approval for Lenalidomide Capsules
The approved Lenalidomide Capsules, bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at Lupin’s Pithampur site in India.
Dexamethasone, | 17/09/2025 | By Dineshwori | 407
Antengene Gets Malaysian Regulatory Agency Approval for XPOVIO Commercialization
Antengene has announced that Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO (selinexor).
Dexamethasone | 06/08/2024 | By Aishwarya | 727
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy